Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan
Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Diabetes Care. 2019 May;42(5):891-902. doi: 10.2337/dc18-1320. Epub 2019 Mar 4.
Clinicopathological characteristics, renal prognosis, and mortality in patients with type 2 diabetes and reduced renal function without overt proteinuria are scarce.
We retrospectively assessed 526 patients with type 2 diabetes and reduced renal function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m), who underwent clinical renal biopsy and had follow-up data, from Japan's nationwide multicenter renal biopsy registry. For comparative analyses, we derived one-to-two cohorts of those without proteinuria versus those with proteinuria using propensity score-matching methods addressing the imbalances of age, sex, diabetes duration, and baseline eGFR. The primary end point was progression of chronic kidney disease (CKD) defined as new-onset end-stage renal disease, decrease of eGFR by ≥50%, or doubling of serum creatinine. The secondary end point was all-cause mortality.
Eighty-two patients with nonproteinuria (urine albumin-to-creatinine ratio [UACR] <300 mg/g) had lower systolic blood pressure and less severe pathological lesions compared with 164 propensity score-matched patients with proteinuria (UACR ≥300 mg/g). After a median follow-up of 1.9 years (interquartile range 0.9-5.0 years) from the date of renal biopsy, the 5-year CKD progression-free survival was 86.6% (95% CI 72.5-93.8) for the nonproteinuric group and 30.3% (95% CI 22.4-38.6) for the proteinuric group (log-rank test < 0.001). The lower renal risk was consistent across all subgroup analyses. The all-cause mortality was also lower in the nonproteinuric group (log-rank test = 0.005).
Patients with nonproteinuric diabetic kidney disease had better-controlled blood pressure and fewer typical morphological changes and were at lower risk of CKD progression and all-cause mortality.
2 型糖尿病伴肾功能下降(估算肾小球滤过率[eGFR]<60mL/min/1.73m2)而无显性蛋白尿患者的临床病理特征、肾脏预后和死亡率较为少见。
我们回顾性评估了来自日本全国多中心肾活检登记处的 526 名 2 型糖尿病伴肾功能下降(eGFR<60mL/min/1.73m2)且接受临床肾活检并有随访数据的患者。为了进行对比分析,我们使用倾向评分匹配方法从无蛋白尿组和蛋白尿组中分别得出了一对一和一对二的队列,以解决年龄、性别、糖尿病病程和基线 eGFR 的不平衡问题。主要终点是慢性肾脏病(CKD)的进展,定义为新发终末期肾病、eGFR 下降≥50%或血清肌酐加倍。次要终点是全因死亡率。
82 名非蛋白尿患者(尿白蛋白与肌酐比值[UACR]<300mg/g)的收缩压较低,病理损伤较轻,与 164 名蛋白尿(UACR≥300mg/g)患者相比,匹配后差异有统计学意义。从肾活检日期起中位随访 1.9 年(四分位距 0.9-5.0 年)后,非蛋白尿组的 5 年 CKD 无进展生存率为 86.6%(95%CI 72.5%-93.8%),蛋白尿组为 30.3%(95%CI 22.4%-38.6%)(对数秩检验<0.001)。所有亚组分析均显示,非蛋白尿组的肾脏风险较低。非蛋白尿组的全因死亡率也较低(对数秩检验=0.005)。
非蛋白尿性糖尿病肾病患者的血压控制较好,典型形态学改变较少,CKD 进展和全因死亡率的风险较低。